JP2014516538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516538A5 JP2014516538A5 JP2014512143A JP2014512143A JP2014516538A5 JP 2014516538 A5 JP2014516538 A5 JP 2014516538A5 JP 2014512143 A JP2014512143 A JP 2014512143A JP 2014512143 A JP2014512143 A JP 2014512143A JP 2014516538 A5 JP2014516538 A5 JP 2014516538A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cells
- patient
- full
- epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490505P | 2011-05-26 | 2011-05-26 | |
| US61/490,505 | 2011-05-26 | ||
| PCT/US2012/039605 WO2012162620A1 (en) | 2011-05-26 | 2012-05-25 | Modulated immunodominance therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516538A JP2014516538A (ja) | 2014-07-17 |
| JP2014516538A5 true JP2014516538A5 (enExample) | 2015-07-02 |
Family
ID=46208182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512143A Pending JP2014516538A (ja) | 2011-05-26 | 2012-05-25 | 調節された免疫優勢療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US20140099341A1 (enExample) |
| EP (2) | EP2714072A1 (enExample) |
| JP (1) | JP2014516538A (enExample) |
| KR (2) | KR20140068810A (enExample) |
| CN (2) | CN103906531A (enExample) |
| AU (4) | AU2012258603A1 (enExample) |
| HK (1) | HK1199404A1 (enExample) |
| RU (1) | RU2013157923A (enExample) |
| SG (2) | SG10201604236RA (enExample) |
| TW (3) | TW201313902A (enExample) |
| WO (1) | WO2012162620A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475578A (zh) * | 2016-05-25 | 2019-03-15 | 昆士兰医学研究所理事会 | 使用同种异体t细胞治疗自身免疫疾病的方法 |
| EP3465203B1 (en) | 2016-05-25 | 2026-03-18 | The Council of the Queensland Institute of Medical Research | Methods of immunotherapy |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| AU2017290119A1 (en) * | 2016-06-28 | 2019-01-24 | Geneius Biotechnology, Inc. | T cell compositions for immunotherapy |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| EP3700553A1 (en) | 2017-10-23 | 2020-09-02 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| AU2022317039A1 (en) * | 2021-07-30 | 2024-02-08 | Tevogen Bio, Inc. | Methods for developing cd3+cd8+ cells against multiple viral epitopes for treatment of viral infections including variants evolving to escape previous immunity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0914142B9 (en) | 1996-03-11 | 2012-01-04 | Epimmune Inc. | Peptides with increased binding affinity for at least three hla-a3-like molecules |
| JP2001509677A (ja) * | 1997-01-31 | 2001-07-24 | エピミューン，インコーポレイティド | Ｃｔｌを活性化するためのペプチドおよびペプチド担持抗原提示細胞 |
| CA2330678C (en) | 1998-05-11 | 2009-04-07 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
| KR100731820B1 (ko) * | 1998-10-05 | 2007-06-25 | 파멕사 에이/에스 | 치료적 백신화를 위한 새로운 방법 |
| CN1440462A (zh) * | 2000-04-28 | 2003-09-03 | 麦康公司 | 鉴定和生产抗原肽的方法并且将其用作疫苗 |
| FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
| AU2003275767A1 (en) | 2002-11-07 | 2004-06-07 | Johnson & Johnson Research Pty Limited | A means of producing and utilising a population of disease specific cytotoxic T-lymphocytes |
| CN100591761C (zh) * | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| WO2006071989A2 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes |
| EP2385059A3 (en) * | 2005-06-17 | 2012-02-15 | Mannkind Corporation | Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
-
2012
- 2012-05-25 HK HK14113011.2A patent/HK1199404A1/xx unknown
- 2012-05-25 SG SG10201604236RA patent/SG10201604236RA/en unknown
- 2012-05-25 RU RU2013157923/10A patent/RU2013157923A/ru not_active Application Discontinuation
- 2012-05-25 KR KR1020137034616A patent/KR20140068810A/ko not_active Ceased
- 2012-05-25 CN CN201280037470.4A patent/CN103906531A/zh active Pending
- 2012-05-25 SG SG10202012534VA patent/SG10202012534VA/en unknown
- 2012-05-25 KR KR1020167023641A patent/KR20160104753A/ko not_active Ceased
- 2012-05-25 EP EP12725589.1A patent/EP2714072A1/en not_active Withdrawn
- 2012-05-25 CN CN201911266293.7A patent/CN111529697A/zh active Pending
- 2012-05-25 AU AU2012258603A patent/AU2012258603A1/en not_active Abandoned
- 2012-05-25 EP EP23158828.6A patent/EP4285922A1/en active Pending
- 2012-05-25 JP JP2014512143A patent/JP2014516538A/ja active Pending
- 2012-05-25 WO PCT/US2012/039605 patent/WO2012162620A1/en not_active Ceased
- 2012-05-25 US US14/122,036 patent/US20140099341A1/en not_active Abandoned
- 2012-05-28 TW TW101118979A patent/TW201313902A/zh unknown
- 2012-05-28 TW TW111127515A patent/TW202321442A/zh unknown
- 2012-05-28 TW TW108117367A patent/TWI774957B/zh active
-
2016
- 2016-10-28 US US15/337,506 patent/US20170042999A1/en not_active Abandoned
- 2016-10-28 US US15/337,661 patent/US20170043001A1/en not_active Abandoned
- 2016-10-28 US US15/337,620 patent/US20170043000A1/en not_active Abandoned
- 2016-10-28 US US15/337,415 patent/US20170042998A1/en not_active Abandoned
- 2016-10-28 US US15/337,556 patent/US20170101625A1/en not_active Abandoned
-
2017
- 2017-04-13 US US15/486,864 patent/US11723921B2/en active Active
- 2017-05-31 AU AU2017203671A patent/AU2017203671A1/en not_active Abandoned
-
2019
- 2019-03-01 AU AU2019201456A patent/AU2019201456A1/en not_active Abandoned
-
2021
- 2021-02-10 AU AU2021200831A patent/AU2021200831A1/en not_active Abandoned
-
2023
- 2023-06-28 US US18/343,693 patent/US20240189353A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abbott et al. | Cancer and the immune system: the history and background of immunotherapy | |
| Su et al. | Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models | |
| Maue et al. | An ESAT-6: CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis | |
| Tian et al. | Luteolin as an adjuvant effectively enhances CTL anti-tumor response in B16F10 mouse model | |
| JP2005523277A (ja) | 癌の治療 | |
| Herrada et al. | Harnessing DNA-induced immune responses for improving cancer vaccines | |
| Lim et al. | DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors | |
| Becker et al. | Skin vaccination with live virus vectored microneedle arrays induce long lived CD8+ T cell memory | |
| Bhattacharyya et al. | Immunological interactions in radiotherapy—opening a new window of opportunity | |
| Toubaji et al. | The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection | |
| Freitas-Silva et al. | Dendritic cell-based approaches in the fight against diseases | |
| Lu et al. | Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model | |
| JP2018016651A (ja) | 能動免疫療法のためのＴｈ１ワクチン接種プライミング | |
| Grasse et al. | GM-CSF improves the immune response to the diphtheria-component in a multivalent vaccine | |
| Holmes et al. | Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I‐01 and I‐02 | |
| Nguyen et al. | Therapeutic cancer vaccines and combination immunotherapies involving vaccination | |
| RU2013157923A (ru) | Терапия на основе модулирования иммунодоминантности | |
| Brody et al. | Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors | |
| Dai et al. | Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice | |
| US20110319871A1 (en) | Infectious disease cellular immunotherapy | |
| WO2006033991A1 (en) | Dendritic cell tumor injection (dcti) therapy | |
| Pawelec et al. | Impact of aging on cancer immunity and immunotherapy | |
| Locy et al. | Dendritic cells: the tools for cancer treatment | |
| Zhang et al. | Enhancement of antitumor immunity using a DNA-based replicon vaccine derived from Semliki Forest virus | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. |